Fusion Antibodies News
New Monoclonal Antibodies production pricing
Fusion Antibodies are today announcing a revision to its service offering for production of Monoclonal Antibodies.
With these changes we hope to allow greater flexibility and options to a wider variety of clients and reduce the barriers…
Fusion Antibodies and Pepscan announce collaboration
Fusion Antibodies have today announced a partnership with Dutch biotechnology company Pepscan to offer the companies CLIPS epitope mapping platform to Fusion Antibodies Customers.
Pepscan is the inventor of epitope mapping with arrays of…
Bizcom Japan and Fusion Antibodies announce collaboration
BizCom Japan, Inc. and Fusion Antibodies Ltd have agreed a Distribution and Marketing Agreement for services and products of Antibody Sequencing and Humanization in Japan.
BizCom Japan, Inc., a privately-held Japan-based trading and consulting…
Fusion Antibodies announce F.A.A.S.T. sequencing service
The Fusion Antibodies Accelerated Sequencing Technology service will offer an option to researches and SMEs
Today we have proudly announced a new, lower-cost, rapid turnaround Antibody Sequencing service. The new F.A.A.S.T (Fusion Antibodies…
Merry Christmas and Happy New Year
Merry Christmas and Happy New Year from Fusion!
Fusion Antibodies would like to wish everyone a Merry Christmas and a Happy New year. Instead of sending out Christmas cards this year Fusion Antibodies have made a donation to Cancer…
Fusion Antibodies develop new technologies with support of InvestNI
Invest NI has offered the company R&D support of £22,704 with an additional £46,600 offered to support a broad range of market development activities.
Fusion Antibodies Ltd is helping to turn leading-edge research into novel drugs…
Fusion Antibodies supports Movember
Fusion antibodies CTO Dr Richard Buick has pledged to raise awareness for men’s health issues and will grow a moustache throughout November.
Fusion Antibodies Ltd has today announced a donation to support the worldwide Movember foundation.…
Fusion Antibodies announce partnership with ISCA diagnostics
Fusion Antibodies CDRx platform has rapidly developed high quality humanized antibodies for Exeter based company Isca Diagnostics.
The EU funded project will allow ISCA Diagnostics to provide the healthcare profession with easy access to…
The CDRx Platform
Fusion Antibodies have developed a next generation computer platform for rapid, high quality generation of humanized antibodies.
The CDRx platform modernizes the traditional CDR grafting technique by in silico grafting parental…
fsn0503 poster at Molecular Targets & Cancer Therapeutics conference
Our Fsn0503 poster will be displayed at this year's International Conference on Molecular Targets and Cancer Therapeutics
Our poster for “Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment…
Fusion Antibodies announces collaboration with Calypso Biotech
Fusion Antibodies Ltd have today announced a collaboration with Swiss biotech company Calypso Biotech for development of their CALY-002 Antibody.
Belfast UK and Geneva Switzerland – 22nd July 2013 – Fusion Antibodies Ltd have today…
Upcoming events in 2013
Here are some of the events Fusion Antibodies will be attending in 2013
Happy New Year Everyone!
Here are some of the events Fusion Antibodies will be attending in 2013:
BioEurope Spring 2013 - http://www.ebdgroup.com/bes/ -…
